Gene editing strategies, from epigenetic engineering to cell reprogramming and genetic vaccines, are accelerating the development of new therapies that awaken the immune system to treat cancer, as ...

The nearer-looming threat of a biosimilar from Amgen Inc. to heavyweight Regeneron Pharmaceuticals Inc.’s age-related macular ...

Through September 2024, biopharma firms secured $720.56 million in nonprofit deals, up in value through July and also marking ...

The drug and device industries have a lot hinging on the results of the Nov. 5 U.S. presidential and congressional elections.

Previous studies have shown that NETosis, a specialized form of neutrophil-specific cell death, is involved in the ...

Collagen-producing activated myofibroblasts, which are key effector cells in fibrogenesis in different organs, express high ...

Researchers from Mariana Oncology Inc. reported preclinical data on MC-339, a DLL3-targeting macrocyclic peptide in several ...

Cell and gene therapy companies are the beneficiaries of positive changes along the regulatory path that the U.S. FDA is ...

Hepatoblastoma is the most common pediatric liver cancer and has limited therapeutic options, with platin-based therapy ...

Some studies suggest a need for cardiologists to rethink their approach to device implant. However, the TAVR UNLOAD study ...

Two days after Monte Rosa Therapeutics Inc. signed a molecular glue degrader deal with Novartis AG, two other companies, ...

The ACURATE study of the Accurate neo2 TAVR device by Boston Scientific Corp., failed to demonstrate the device is ...